Deep Breath is the official newsletter of the UKs Refactory Asthma Stratification Programme and you can read our first issue here [1].
Our consortium of research, academic and industry parties are focused on finding new treatment paradigms for asthma. We see the future of severe asthma management involving treatment optimisation to individual patients fully utilising currently available treatments more efficiently, particularly with corticosteroids by defining an ‘optimised’ dose, allied with the use of ‘add-on’ target-specific novel treatments. At present there seems to a “tsunami” of novel treatments aimed at targeting Type-2 cytokine mediated inflammation approaching introduction in the clinic. Understanding where these new treatments will fit into the current management is likely to define our therapeutic journey in the coming years. This new ‘era’ and our collaborative efforts in this UK clinical research programme will hopefully deliver better management for our patients as well as contribute to the identification of novel targets in this exciting era of stratified medicines in severe asthma.
This newsletter gives a description of the various different work strands on the initiative and their objectives, introduces key team members and provides an update on the progress being made by each of the different aspects of the project. There is a brief report on the first RASP-UK General Assembly Meetng held on 1st December 2015 at One Drummond Gate, Victoria, London. This was the first time all consortium leaders and key members of their teams had gathered in one place and it was a great opportunity for the consortium to share their experience, cement relationships that will foster collaboration and receive updates from the leadership team relating to the RASP-UK programme. One of the key objectives of the bringing the teams together was to introduce the multidisciplinary teams to the concept of achieving project legacy through a strategically targeted process of publication planning and communications designed to win share of voice in the rapidly developing field of asthma treatment. Further information can be found on the consortium website [2].
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
ive years ago I was lucky enough to be involved in a project that resulted in publications
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
